Please submit your clinical topic for the next GU CONNECT newsletter here.
As an experienced urologist and member of GU CONNECT, Prof. David Pfister provides his perspective on new therapies for mHSPC.
Assoc. Prof. Tanya B. Dorff looks into the use of imaging along with the treatment of oligometastatic prostate cancer.
Asst. Prof. Shilpa Gupta discusses the newly defined criteria for “platinum-ineligibility” in patients with metastatic urothelial cancer on behalf of the Platinum-Ineligibility in Bladder Cancer Working Group.
Dr. Tia Higano provides her perspective on ERA 223: A phase 3 trial of Ra-223 in combination with AAP in the treatment of asymptomatic or mildly symptomatic chemotherapy-naïve patients with bone-predominant mCRPC.
Associate Professor Alicia Morgans provides her thoughts on the recent advances in metastatic hormone-sensitive prostate cancer.
Professor of Medicine Evan Yu and Associate Professor Tanya Dorff provide their thoughts and views on combination, sequential and immuno-oncology therapies in mCRPC (Metastatic Castration-Resistant Prostate Cancer).
An update on recent cutting-edge trials: Treatments now available for newly diagnosed mHSPC patients
Dr. Neal Shore, Assoc. Prof. Neeraj Agarwal and Prof. Steven Joniau provide their thoughts and views on treatments for newly diagnosed mHSPC (Metastatic Hormone Sensitive Prostate Cancer) patients following recent cutting-edge trials.